`
`
`EXHIBIT 5 TO NUVASIVE, INC.’S
`NOTICE OF LODGMENT OF WITNESS
`DEPOSITION DESIGNATION CLIP REPORTS
`
`
`
`Case 3:18-cv-00347-CAB-MDD Document 395-5 Filed 03/10/22 PageID.34813 Page 2 of 2
`
`
`
`
`NuVasive v. Alphatec
`
`Howell, Kelli (Vol. 01) - 06/01/2018
`1 CLIP (RUNNING 00:00:51.421)
`
`Other than neuromonitoring, is there ...
`
`1 SEGMENT (RUNNING 00:00:51.421)
`KH093L15
`1. PAGE 93:15 TO 94:04 (RUNNING 00:00:51.421)
` 15 Q. Other than neuromonitoring, is there
` 16 anything else about the XLIF platform that
` 17 contributes to desirable clinical outcomes?
` 18 A. Again, from an assembly standpoint, all
` 19 of it. Does a surgeon like certain features to
` 20 make it less fiddly, that saves them time in the
` 21 procedure, familiarity with the system. Again,
` 22 being an early entrant to the market, having the
` 23 benefit of experience with the platform, gaining
` 24 those biases to certain design elements of it, our
` 25 features of functionality or how things work during
` 00094:01 the procedure. All of that, I think, results in
` 02 what the ultimate outcome looks like and the
` 03 ability to demonstrate whether an outcome is better
` 04 or worse.
`
`TOTAL: 1 CLIP FROM 1 DEPOSITION (RUNNING 00:00:51.421)
`
`CONFIDENTIAL
`
`page 1
`
`